3Chan H L, Wang H, Niu J, et al. Two-year Lamivudine Treatment for Hepatitis B e Antigen-negative Chronic Hepatitis B: a Double-blind, Placebo-controlled Trial[J]. Antivir Ther, 2007, 12(3) : 345-353.
4Hadziyannos S,Tassopulous N,Chang T Y,et al. Three Years Study of Adefovir Dipivoxil (ADV) Demonstrates Sustained Efficacy in Plesumed Precore Mutant Chronic Hepatitia B Padents in a Long Safety and Efficacy Study[J]. Hepatol, 2004, 40(Suppl 1):A17.
5Hadziyannis S J, Tassopoulos N C, Heathcote E J, et al. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-negative Chronic Hepatitis B[J]. N Engl J Med,2003,348(9):800- 807.
6Lampertico P, Vigano M, Manenti E, et al. Low Resistance to Adefovir Combined with Lamivudine: a 3-year Study of 145 Lamivudine-resistant Hepatitis B Patients[J]. Gastroenterology, 2007,133:1445-1451.
7Shouval D. Entecavir Demonstrates Superior Histologic and Virologic Efficacy Over Lamivudine in Nucleoside-naive HBeAg(+) Chronic Hepatitis B: Results of Phase III Trial ETV 027[J]. Hepatol,2004,40(Suppl 1 ) : A728.
8Rosmawati M. Entecavir is Superior to I.amivudine at Reducing HBV DNA in Patients with Chronic Hepatitis B Regardless of Baseline Alanine Aminotransferase Levels[J]. Hepatol, 2004, 40(Suppl 11):A616.
10Lai C L,Gane E,Hsu C W,et al. Two-year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine vs Lamivudine[J]. Hepatol, 2006,44 ( Suppl 1 ): A222.
二级参考文献12
1Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs, 2003, 12: 683-688.
2Seifer M, Hamatake RK, Colonno RJ, et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475and lobucavir. Antimicrob Agents Chemother, 1998, 42: 3200-3208.
3de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology, 2001, 34: 578-582.
4Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 2002, 123: 1831-1838.
5Marion PL, Salazar FH, Winters MA, et al. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother, 2002, 46: 82-88.
6Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol, 2005, 42: 302-308.
